Effectiveness and Safety of Xeligekimab in Adult Patients with Moderate to Severe Plaque Psoriasis: a Multicenter, Prospective, Real-World Study
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Xeligekimab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Genrix (Shanghai) Biopharmaceuticals
- 04 Feb 2025 New trial record